At B. Riley, our research process is an interactive one where we perform extensive due diligence on companies until the analyst develops the knowledge base and understanding of the company and the industry to make a recommendation. Our analysts continuously monitor industry developments and communicate with the management, competitors, suppliers and customers of the companies we follow, regularly communicating our findings through Research Updates and daily Morning Notes.

While we do not necessarily publish research on all of the companies we review, the knowledge base and understanding of many of our monitored companies parallels that of our covered companies. We actively cover over 100 companies and monitor an additional 100. Our analysts cover small to mid-cap companies that are under-followed or misunderstood by Wall Street. We believe that the pricing of small cap equities is frequently inefficient, and therefore provides the greatest potential rewards to diligent security analysis.

This Week's Research

  • 12/18/14 Morning Note B. Riley & Co. Morning Notes: GRPN, IDSY, TUP; Exhibition Sector (AMC, CKEC, CNK, IMAX, MCS, RGC, RLD)
  • 12/18/14 Update GRPN ($7.19, Buy; $9.75 PT): Coupang Funding Valuation Reaffirms our Value of Asian Assets at $2.50 per Share and Implies Core Business is Undervalued;…
  • 12/17/14 Update BRKS ($12.10, Buy; $14.50 PT): Catching Up With BRKS, Digging Into The Life Sciences Business
  • 12/17/14 Update Industry Update - Household/Personal Care: Weekly Highlights (ANF, AVP, CLX, IPAR, NTRI, ORI-Sweden, WDFC)
  • 12/17/14 Morning Note B. Riley & Co. Morning Notes: BRKS, IPAR, MTSN, SABA; Consumer Products Weekly (AVP, CLX, IPAR, NTRI, WDFC), Media (AMC, CKEC, CNK, MCS, RGC)
  • 12/17/14 Update MTSN ($3.12, Buy; $3.50 PT): Upcoming SAM Expansion Bodes Well For Long Term Growth; Buy
  • 12/17/14 Update SABA ($8.75, Buy; $12.75 PT): Strategic Assets, Near-Term M&A Potential and Valuation too Compelling to Ignore; Upgrading to Buy Rating
  • 12/17/14 Update Industry Update: Media - Threats Around “The Interview” Adds Risk to Already Weak Q4/Q1 Outlooks
  • 12/16/14 Update IPAR ($25.32, Buy; $35.00 PT): Share Price +5% at Mid-Day on A&F Fragrance Partnership
  • 12/16/14 Update CKEC ($25.50, Buy; $40.00 PT): Excessive Post-Thanksgiving Drop in CKEC Shares Provides Compelling Entry Point Even with Expected Near-Term Box Office…
  • 12/16/14 Update NTRI ($19.14, Buy; $25.00 PT): Update As We Approach Diet Season 2015
  • 12/16/14 Morning Note B. Riley & Co. Morning Notes: ABTL, CKEC, NTRI, PCMI, SABA, TREC; Semiconductors (ADI, AOSL, EXAR, ISSI, INTC, ISIL, LLTC, MRVL, MXIM, MCHP, NVDA,…
  • 12/16/14 Update SABA ($13.49, Neutral; $12.75 PT): Provides Company and Restatement Update; Reducing Price Target from $15.50 to $12.75; Maintain Neutral
  • 12/16/14 Update Industry Update: Semis And Cap Eqp - View From Asia Corroborates Seasonal Chip Order Activity
  • 12/15/14 Update PCMI ($9.05, Buy; $13.00 PT): Management Meetings Highlight Growth Potential
  • 12/15/14 Update AKAM ($60.84, Buy; $70.00 PT): Leverage to Video Ecosystem Should Drive 2015 Momentum Despite Tough Comps; Adjusting Estimates for FX and Strength…
  • 12/15/14 Morning Note B. Riley & Co. Morning Notes: AKAM, IMAX, RLD, TROX; Exhibitor Sector (AMC, CNK, IMAX, RLD, RGC)
  • 12/15/14 Update TROX ($21.75, Buy; $29.00 PT): Lowering FY ’15 Estimates But Inorganic Growth Catalysts Make Risk/Reward Favorable & 4.6% Yield Makes it Pay to…
  • 12/12/14 Update ZQK ($1.48, Neutral; $3.30 PT): Light Q4 sales, better SG&A; EBITDA in line with consensus; lower/cleaner inventory, ~$160MM in liquidity; improved…
  • 12/12/14 Update DWA ($21.71, Neutral; $25.00 PT): Lowering 2014/2015 Estimates for Weak Penguins Results and Expected Release Date Shifts; Cautious on Outlook, but…
  • 12/12/14 Update RUBI ($13.49, Buy; $21.00 PT): Receives High Grade for Quality of Traffic; Competitive Advantages Starting to Strengthen
  • 12/12/14 Morning Note B. Riley & Co. Morning Notes: CIDM, CLX, DWA, EMKR, LRCX, MEI, RSH, RUBI, SWKS, ZQK
  • 12/12/14 Update LRCX ($79.80, Buy; $95.00 PT): Excess Growth Confidence Remains High, Increase Target To $95.0
  • 12/12/14 Update MEI ($35.65, Buy; $47.00 PT): Solid Beat and Another Guidance Raise; Odd Sell-Off Creates Opportunity; Reiterate Buy and $47 PT
  • 12/12/14 Update EMKR ($5.06, Buy; $6.50 PT): Fiber Optics Heating Up; Raising Estimates and Maintaining PT of $6.50; Reiterate Buy
  • 12/12/14 Update SWKS ($70.08, Buy; $83.00 PT): Revisiting Growth And Valuation Case And Lifting PT To $83.0 From $74.0
  • 12/12/14 Update CLX ($100.92, Neutral; $83.00 PT): Structural Headwinds Abating, But Commodities Not Yet a Tailwind
  • 12/12/14 Update RSH ($0.51, Sell; $0.00 PT): Weak 3Q And Lender Pushback Offset A Few Favorable Developments